radiation therapy in prostate cancer
DESCRIPTION
Newer technological innovation in Radiation therapy has revolutionized Prostate Cancer treatment. Presented in IMA Bangalore 2014TRANSCRIPT
![Page 1: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/1.jpg)
Radiation Therapy in Prostate Cancer
Lokesh Viswanath M.D.Professor, Radiation Oncology, Kidwai Memorial Institute of Oncology 2014
![Page 2: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/2.jpg)
Prostate Cancer• World wide :
– Second most common cause of cancer– New Cases ~ 1.1 million (15%)– Developed countries ~ 70%– 307,000 deaths
• Prostate cancer incidence – Lowest:
• Asian populations 10.5 per 100,000 • Eastern and South-Central Asia 4.5 per 100,000
– Highest : • 111.6 Australia/New Zealand and • 97.2 per 100,000 Northern America
![Page 3: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/3.jpg)
![Page 4: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/4.jpg)
In India• Previously – thought - prevalence of prostate cancer in India
is far lower compared to western countries • but …
– increased migration rural to urban areas– changing life styles– increased awareness– easy access to medical facility
…..– more cases of prostate cancer are being picked up
– we are not very far behind the rate from western countries.
– Current incidence rate of prostate cancer in India is ~ 10.66 per 100000 population
![Page 5: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/5.jpg)
Current India Data: • Prostate cancer:
– 2nd leading site of - Delhi, Kolkatta, Pune and Thi'puram– 3rd leading site of Bangalore and Mumbai
Projected cases of prostate cancer for selected time periods (2013, 2014, 2015 and 2020).ICD-10 Site name 2013 2014 2015 2020C61 Prostate 35,029 37,055 39,200 51,979
![Page 6: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/6.jpg)
Prostate : Anatomy • Prostate
– Accessory gland– Inverted Cone encompasses the p. urethra– Dense fibromuscular stroma– Surrounded by a capsule – 4 x 3 x 2cms– 8g
• Prozimity to Rectum & U Bladder– Denonvilliers fascia
• Blood supply– Inferior vesical – Mid rectal– Internal pudendal
• Lymphatics– Internal iliac nodes– Sacral– Partly external iliac nodes
Nervous supply– Neurovascular bundle
• Lies on either side of the prostate on the rectum– Derived from the pelvic plexus - Important for erectile function.
![Page 7: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/7.jpg)
Epidemiology • Risk factors
– Increasing age– Family history– African-American– Dietary factors.
• Race– Incidence doubled in African Americans compared to white Americans.
• Genetics– Common among relatives with early-onset prostate cancer– Susceptibility locus
• Chromosome 1, band Q24• Found in < 10% of prostate cancer patients
• Nutritional factors - protective effect against prostate cancer– Reduced fat intake– Soy protein– Lycopene– Vitamin E– Selenium
![Page 8: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/8.jpg)
Clinical Manifestations : Symptoms • Early state (organ confined)
– Asymptomatic• Locally advanced
– Obstructive voiding symptoms • Hesitancy• Intermittent urinary stream• Decreased force of stream
– May have growth into the urethra or bladder neck – Hematuria – Hematospermia
• Advanced (spread to the regional pelvic lymph nodes)– Edema of the lower extremities– Pelvic and perineal discomfort
![Page 9: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/9.jpg)
Clinical Manifestations : 2• of Metastasis :
– Most commonly to bone (frequently asymptomatic)• Can cause severe and unremitting pain
– Bone metastasis • Can result in pathologic fractures or • Spinal cord compression
– Visceral metastases (rare)– Can develop pulmonary, hepatic, pleural, peritoneal, and
central nervous system metastases late in the natural history or after hormonal therapies fail.
![Page 10: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/10.jpg)
Clinical Signs
• Routine Clinical history and clinical examination Rectal examination
• Signs: PR examination - Abnormal • ( +ve for Malignancy 25-50%)
• Hard nodule / extremely firm• Evaluate for disease extension in
– Lateral sulcus– superior
![Page 11: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/11.jpg)
Presentation
• Peripheral zone (PZ)– 70% of cancers
• Transitional zone (TZ)– 20% – Some
• TZ prostate cancers are relatively nonaggressive• PZ cancers are more aggressive
– Tend to invade the periprostatic tissues.
![Page 12: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/12.jpg)
InvestigationsRoutine: Laboratory
Complete blood cell count, blood chemistry Serum PSA (total, free, complex PSA:: ratio of Free : Total PSA < 0.2 - likely Prostate Ca. )
(Normal Age-Specific Limits for PSA - Plasma acid phosphatases (prostatic/total) Testosterone
Other Experimental:RT PCR for mRNA of PSA & PSMA
+ve - Extraprostatic – 72%-ve - Organ confined - 88%
![Page 13: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/13.jpg)
Staging Tests1. Magnetic resonance imaging (MRI) –
defn Apex, NV bundle, ano rectal wall, intra prostatic dises location, capsular extension, seminal vesicle involvement
1. T2 axial / coronal : neurovascular bundle , penile bulb2. PZ - T2 Normal – high signal , Tumor – Low signal , T1 – Hemorrhage – Low
signal intensity3. Extracapsular extension : focal, irregular capsular bulge, invasion of NV bundle,
obliteration of rectoprostatic angle4. endorectal MRSI – MR spectroscopy : metabolic activity and extra capsular
extension, seminal vesicle invasion : Increase coline
2. Transrectal ultrasound (TRUS) : » Ca – variable echo, hyper – 69%, margin - poorly defined ,
3. Transrectal or transperineal biopsy : – 16 guage , 10 -18 core (base, apex, both lateral, mid, lat peripheral zone)– Core length
4. Chest radiograph (high risk for metastatic disease)5. Computed tomography (CT) scans – pelvis node assesment
6. Radionuclide bone scans : Indicated: PSA>20, Gleason score ≥8, Bone pain
Other:
1. PET/CT with 11C- Acetate - detecting microscopic +LN
![Page 14: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/14.jpg)
Others : essential base line evaluation
• Erectile function• Bowel : SI/LI/Rectum/Anal Sphincters• Bladder : Flow/rate
![Page 15: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/15.jpg)
AJCC / TNM Stage Groupings Definitions
![Page 16: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/16.jpg)
![Page 17: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/17.jpg)
Pathology• Adenocarcinoma 95% - peripheral acinar glands• Other Histologic Subtypes
– Periurethral duct carcinoma– transitional cell carcinoma – Ductal adenocarcinoma – Neuroendocrine tumors – Mucinous carcinoma– Sarcomatoid carcinoma – Endometrioid tumors – Adenoid cystic carcinoma – Sarcomas (leiomyosarcoma, rhabdomyosarcoma, or fibrosarcoma) – Carcinosarcoma – Primary lymphoma
![Page 18: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/18.jpg)
Evaluation of the histologic grade ('G')
GX: cannot assess gradeG1: the tumor closely resembles normal tissue (Gleason 2–4)G2: the tumor somewhat resembles normal tissue (Gleason 5–6)G3–4: the tumor resembles normal tissue barely or not at all
(Gleason 7–10)
![Page 19: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/19.jpg)
• histological patterns, emphasizing degree of glandular differentiation and relation to stroma
• Histologic patterns 1 through 5• nine discrete scores (range, 2 to 10)• one of the strongest predictors of
– biologic behavior in prostate cancer– invasiveness – metastatic potential– < 6
Gleason score
![Page 20: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/20.jpg)
Prostate Cancer Risk Groups :- stage : PSA : Gleason score
![Page 21: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/21.jpg)
Treatment options for prostate cancer
• Observation alone
• Radical prostatectomy
• Radiation therapy
• Hormonal treatment
![Page 22: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/22.jpg)
Overview Treatment Options by Stage for Prostate CancerStage ( AJCC TNM Staging Criteria) Standard Treatment Options
Stage I •Watchful waiting or active surveillance
•Radical prostatectomy
•External-beam radiation therapy (EBRT)
•Interstitial implantation of radioisotopes
Stage II •Watchful waiting or active surveillance
•Radical prostatectomy
•External-beam radiation therapy (EBRT) with or without hormonal therapy
•Interstitial implantation of radioisotopes
Stage III •External-beam radiation therapy (EBRT) with or without hormonal therapy
•Hormonal manipulations (orchiectomy or luteinizing hormone-releasing hormone [LH-RH] agonist)
•Radical prostatectomy with or without EBRT
•Watchful waiting or active surveillance
Stage IV •Hormonal manipulations
•Bisphosphonates
•External-beam radiation therapy (EBRT) with or without hormonal therapy
•Palliative radiation therapy
•Palliative surgery with transurethral resection of the prostate (TURP)
•Watchful waiting or active surveillance
Recurrent •Chemotherapy for hormonal management of prostate cancer
•Immunotherapy
![Page 23: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/23.jpg)
Indications for RT T N0 N1 M1 PSA GS
SURVELLIANCE SURGERY Radical RT
Radical Brachytherapy HT
T1a + <10 <6 YES RP+ PLND RT BRACY
T1b + <10 <6 YES RP+ PLND
(<2% +ve nodes) RT BRACY
T1c + <10 <6 YES RP+ PLND
(>2% +ve nodes) RT BRACY
T2a + RT + ADT
T2b + RT + ADT
T2c +
10 to 20 7 YES RP+ PLND
RT + ADT + BRACHY BOOST BRACY Y
T3a + >208 to 10 RP+ PLND RT + ADT BRACHY BOOST Y
T3b + RT + ADT BRACHY BOOST Y
T4 + RT + ADT BRACHY BOOST ADT
Any T + RT + ADT Y
Any T / N + RT ADT
![Page 24: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/24.jpg)
Radiation Therapy : Basics
![Page 25: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/25.jpg)
Radiotherapy
![Page 26: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/26.jpg)
• Radiation therapy is the art of using ionising radiation to destroy malignant tumours while being able to minimise damage to normal tissue.
![Page 27: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/27.jpg)
Introduction• Basics of Radiation Therapy
– Ionizing Radiation – X / γ Rays– Interaction of Radiation with matter
Transmission Attenuation
Scatter Absorption
Rad / Gray / cGy
![Page 28: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/28.jpg)
Cancer Cell & Ionizing Radiation
• Cancer cell multiply faster than normal cell• DNA is primary target • Double Strand breaks
>>> Reproductive Cell Death
![Page 29: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/29.jpg)
RT is a Double Edge Sword
![Page 30: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/30.jpg)
↑ RT Dose
↓ RT Dose
↑ T – Control ↓ T – Control
↑ Normal Tissue Toxicitites
↓ Normal Tissue Toxicitites
![Page 31: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/31.jpg)
EQUIPMENTS
![Page 32: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/32.jpg)
Radiation EquipmentsTeletherapy• Telecobalt• Linear Accelerator
– Simple Teletherapy– SRS/SRT– 2D– 3DCRT– IMRT– IGRT– Rapid Arc– FFF– SBRT – 4DRT – Target tracking– Tomotherapy– Cyber Knife
• Gamma Knife
Brachytherapy– Intracavitory– Interstitial– Mould
• Pre Loaded / After loading
• Manual / Remote• LDR / HDR • Permanent Implants
![Page 33: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/33.jpg)
Linear Accelerator• 3DCRT > 1998+• IMRT > 2000+
![Page 34: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/34.jpg)
Linear Accelerator : 3DCRT / IMRT
![Page 35: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/35.jpg)
Tomotherapy - 2003
![Page 36: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/36.jpg)
Synchrony™
camera
Treatment couch
Linearaccelerator
Manipulator
Imagedetectors
X-ray sources
Targeting System
Robotic Delivery System
Cyber Knife – 2003+
![Page 37: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/37.jpg)
IGRT - 2005
![Page 38: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/38.jpg)
True beam - All in One FFF SBRT / 4DRT –
![Page 39: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/39.jpg)
True Beam - 2010
![Page 40: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/40.jpg)
Proton Beam therapy 2012
![Page 41: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/41.jpg)
Brachytherapy
• LDR - Iridium wires – Manual Interstitial <Phased out>
• HDR – Iridium / Cobalt• Permanent Interstitial Implant – Iodine seeds
![Page 42: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/42.jpg)
125 I Seed Implant
![Page 43: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/43.jpg)
HDR - Brachytherapy
![Page 44: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/44.jpg)
RT Planning Process
![Page 45: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/45.jpg)
Radiation Therapy
Prostate Cancer : • Disease Characterization :
• Clinical - KPS/Co-existing Morbidities/TRUS/ CT/MR• TNM/PSA/GS
– Primary – Primary + Regional nodes
• + ADT
PSA (ng/ml) +VE PELVIC NODE YEILD
4-20 < 12%
>20 > 10%
> 25 30-35%
> 50 + high GS 62%
![Page 46: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/46.jpg)
Radiation Therapy : Intent Defn • Radical RT
– RT alone:– Conventional (7-8 weeks) <– Hyperfractionation (5-6 weeks) – Hypofractionation (1-2 Gap 1-2 weeks) < CK / SRS / SBRT – Photons alone
– Recent adv - Photons + Particle (Protons)– Protons alone– RT + Hormon therapy (HT)– RT + Radiation Protectors (Amifostine)– Teletherapy + Brachytherapy Boost– Brachytherapy alone
• Brachy type: Volume implants– Temporary Implant – HDR– Permanaent Implant – I 125
• Post Operative RT (5-7 weeks)• Salvage RT / Re-irradiation• Palliative RT
– Short Course (1day, 1-2 weeks)– Saturation Technique (1-2 weeks gap 3-4 weks)
![Page 47: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/47.jpg)
RT Techniques
• Teletherapy– 2 D– 3 D Conformal– IMRT– IGRT– Tomotherapy– CK SRS / SRT– Rapid arc– SBRT - FFF– Proton
• Bracytherapy– Interstital
• HDR – Ir - Temporary • 125 Iodine - Permanent
![Page 48: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/48.jpg)
Indications for RT in Ca Prostate• Radical RT
– T1, T2, T3, T4a
• Un-resectable (Altered Fractionation HF/CB or RT + HT )• elderly, frail, comorbid conditions• refusal for surgery• prohibitive morbidity due to surgery
• Post OP RT : after Radical Prostatectomy– pT3/4– Close & +ve margin– Extra Capsular extension– Invasion to
• Seminal vesicle• Extraprostatic extensions
– Multiple nodes– R 1 resection
• Pre OP PSA > 10ng/ml• Pre OP PSA velocity > 2ng/ml/year
– Post RP – Recurrent disease– Post RP - early PSA failures
![Page 49: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/49.jpg)
RADIOTHERAPY DOSE
1. External : a. IMRT / IGRT / Rapid Arc / Protons :
– > 7400 cGy to 7600 cGy / 6-8 wks– 180-200cGy / fr, 5fr/wk
b. CK / SBRT / FFF : 5 – 20 Gy / fr, 3-5 fr
c. Post-op.: 60-66 Gy / 6-7 wks
d. Palliative RT: 30Gy/10f, 20Gy/5 or 4f, 7-8Gy/1f
2. Brachytherapy : a. Alone : 6000 - 7000 cGy in 6 to 7 days.
b. External + Brachytherapy Ext : 46-50 Gy in 4 1/2 - 5 1/2 wks. +
Brachy : 2000-3000 cGy in 2-3 days
HDR : 9.5Gy x 2f, as mono therapy 9.5Gy bid x 4f x 2dys
I -125 : 0.2-0.9mCi, T1/2-17dy, 21Kev
![Page 50: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/50.jpg)
RT Dose
• 2D : 66Gy , 1.8-2Gy/f, 5f/wk• 3DCRT : 70-75Gy• IMRT /IGRT : 75 – 81Gy
![Page 51: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/51.jpg)
Patient
![Page 52: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/52.jpg)
RT Planning
• Informed Consent : • Implant Fidutial - +/- (if GC is not favorable CBCT )
• Mould room work : Patient positioning, knee rest• Virtual CT Simulation• Contouring• RT planning• Plan evaluation and acceptance• QA tests
![Page 53: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/53.jpg)
Fidutial Placement
• TRUS Guided• 1 week prior to simulation
![Page 54: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/54.jpg)
Flat Couch
CT Simulator
![Page 55: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/55.jpg)
Instructions for Virtual SimulationMould room techniques:• Bowel / Bladder – post void (full – if u/s Tracking)• Patient Positioning : Supine (↓ P motion) / Prone• Thermoplastic mold – Pelvic cast - knee to mid thigh + Tattooe / Tegaderm• Knee rest
Virtual simulation : Flat Couch– Patient repositioning– Pelvis : pubic symphysis - Laser set (mid / 2 lateral – 5cms post) – marking – Radio-opaque markers– CT Sim - 3mm – Scan : 20-30 cms above & 20-30 cms below the marker plane
![Page 56: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/56.jpg)
Contouring
• Data transfer : from CT sim to RT planning system – DICOM format
• Patient registration : CT data / CT + MR Fusion data• Contouring : Target & Normal tissue
– CTV – P alone / P + SV / P + SV + Pelvic Ly nodes– PTV – CTV + Margin
• Cobalt / 2D / 3DCRT - 2cms• IMRT – 1cms (in all directions except rectal interface – 0.6cms) • IGRT – 0.6 cms all round• CK/SBRT – 0.3 cms all round
– Prostatic apex definition – urethrogram / MRI
![Page 57: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/57.jpg)
On the machine
• Machine QA for the Planned treatment• Patient positioning and verification• Portal Imaging & setup verification + CBCT• Treatment plan execution
• Daily QA• Daily Portal imaging /MV – KV / CBCT / 3D CBCT • Monitoring of Acute radiation reaction and
supportive cares
![Page 58: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/58.jpg)
![Page 59: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/59.jpg)
Beam selection and planning• 2 D :
– AP: PA– AP : PA : RT Lat : Lt Lat
• 3 DCRT : 6 Coplanar ( 2 – lat, 2 Ant & 2 Post Obliques )– Plan evaluation :
• Dose distribution (isocentre) – Transverse / Coronal / Sagittal• DVH• Beam weighing – 2 lat – half the dose• Uniform dose in PTV• Elimination of hot spot from rectum
• Plan normalization : • Prescription iso-dose – 100% coverage of PTV • PTV Hot spot < 6-9% • Rectal volume in PTV 75.6G < 30%• Femur < 68Gy (90%)• Large bowel < 60Gy (79%)• Small bowel < 50 gy (66%)
![Page 60: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/60.jpg)
2D plan – Orthogonal X Ray simulation
![Page 61: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/61.jpg)
• 3DCRT MLC based conformal field
![Page 62: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/62.jpg)
![Page 63: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/63.jpg)
![Page 64: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/64.jpg)
2D RT 3DCRT
IMRT Rapid Arc
Evolution of conformality
![Page 65: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/65.jpg)
![Page 66: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/66.jpg)
TOMOTHERAPY : 78Gy
![Page 67: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/67.jpg)
AMS CONFIDENTIAL
Cyber knife
![Page 68: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/68.jpg)
Rapid Arc
![Page 69: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/69.jpg)
![Page 70: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/70.jpg)
![Page 71: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/71.jpg)
![Page 72: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/72.jpg)
![Page 73: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/73.jpg)
![Page 74: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/74.jpg)
![Page 75: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/75.jpg)
Patient on Treatment
![Page 76: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/76.jpg)
Protons
![Page 77: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/77.jpg)
Proton Therapy vs. IMRT Dosimetric study:
10 IMRT vs.10 proton beam to 78 Gy
Mean rectal dose-volume histograms
Vargas et al. IJROBP 2007
![Page 78: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/78.jpg)
Proton Therapy vs. IMRT
![Page 79: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/79.jpg)
Brachytherapy
![Page 80: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/80.jpg)
Interstitial Brachytherapy
![Page 81: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/81.jpg)
Prostate Brachytherapy
![Page 82: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/82.jpg)
Prostate Brachytherapy
Iodine 125
t ½ = 60 days
Gamma emitter
Energy 35 kV
![Page 83: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/83.jpg)
![Page 84: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/84.jpg)
![Page 85: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/85.jpg)
During RT
![Page 86: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/86.jpg)
Target Motion ITV Management
• Daily localization IGRT techniques to account for interfraction motion:– intraprostatic fiducial markers with daily imaging– transabdominal US– daily in-room CT imaging– endorectal balloon immobilization
• All of these methods employ daily imaging of the prostate in the treatment room.
![Page 87: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/87.jpg)
Target Tracking
• During RT– Celing mounted Cross fired X-Ray / Fluro eg.CK, X Tack–
• Before RT– Orthogonal KV / MV Portal imaging – best with fidutial– CBCT / Onrail CT – suitable for patients without
fidutials
![Page 88: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/88.jpg)
Ceiling mounted Cross fired X Rays
![Page 89: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/89.jpg)
Motion Management
In this technique, the isocenter is shifted until the bony contours (setup error) or the implanted markers are in agreement (total error).
reference (simulation film) online (port film) co-registered (right)
![Page 90: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/90.jpg)
Motion Management Cone beam computerized
tomography (CBCT) allows volumetric visualization of the prostate and adjacent organs. – Daily online correction allows for
PTV margins: • 4 mm in all directions and 3
mm posterior (Pawlowski, Red Journal 2010)
• 5 mm all around and 3 mm posterior (Hammoud, Red Journal 2008)
2 stages of image registration: Top: pelvic bone region of interestBottom: prostate/sv represented by masked area.
![Page 91: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/91.jpg)
Motion Management• Intrafraction Motion
– Changes in position while the treatment beam is on (“second by second”)
– Mostly from peristalsis/gas, pelvic floor movement, respiration coughing, etc.
– Techniques to account for intrafraction motion:• RGRT (radiofrequency-guided RT techniques)• Rectal balloon • Bowel prep (anti-gas tablets and daily bm)• Consistent Bladder filling
![Page 92: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/92.jpg)
![Page 93: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/93.jpg)
![Page 94: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/94.jpg)
![Page 95: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/95.jpg)
![Page 96: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/96.jpg)
![Page 97: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/97.jpg)
![Page 98: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/98.jpg)
![Page 99: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/99.jpg)
![Page 100: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/100.jpg)
![Page 101: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/101.jpg)
Motion management Endorectal balloon
– Used for prostate immobilization/fixation
– Ensures reproducibility of rectal filling and spares posterior rectum
Teh, Red Journal 2001
78 Gy IMRT plans without (left) and with balloon (right) Contours: rectal wall (green), anal wall (purple) and PTV (blue).
![Page 102: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/102.jpg)
Treatment results
![Page 103: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/103.jpg)
PSA relapse free survival rate (%)
~ EBRT RP BRACHY
5 YRS 79 81 98
8 YRS 70 72 92
![Page 104: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/104.jpg)
![Page 105: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/105.jpg)
androgen suppression or androgen deprivation therapy.
![Page 106: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/106.jpg)
most commonly used hormone therapies
• Orchiectomy
Medical Castration - reversible• luteinizing hormone-releasing hormone (LHRH) agonists –
synthetic proteins - similar to LHRH and bind to the LHRH receptor in the pitutary gland- causes the pituitary gland to stop producing luteinizing hormone, which prevents testosterone from being produced- leuprolide, goserelin, and buserelin
• LHRH antagonists - act by preventing LHRH from binding to its receptors in the pitutary gland
![Page 107: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/107.jpg)
Toxicities
Impotence rates• Brachy alone – 24%• Brachy + EBRT – 40%• EBRT alone – 45%• Nerve sparing RP – 66%• RP – 75%• Cryosurgery – 87%
Urinary control• RP – 35%• RT – 97%
![Page 108: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/108.jpg)
Summary and Conclusion
![Page 109: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/109.jpg)
Advances in newer radiation technologies
• Enhanced Normal Tissue Sparing • Reduces side effects
• Dose Escalation has Improved Cure Rate• Higher Dose per Fraction reduces hospital visits
• Reduce Number of fractions• Reduce Treatment Duration
![Page 110: Radiation therapy in prostate cancer](https://reader038.vdocuments.us/reader038/viewer/2022102716/5563c8cdd8b42ad6088b472d/html5/thumbnails/110.jpg)
Thank you